BioCentury
ARTICLE | Clinical News

ACTOplus Metpioglitazone/metformin regulatory update

September 24, 2007 7:00 AM UTC

CHMP recommended removing a contraindication from the label of Competact pioglitazone/metformin warning against concurrent administration with insulin in patients with Type II diabetes. Takeda markets the peroxisome proliferation activated receptor (PPAR) gamma agonist and metformin fixed dose combination as ACTOplus Met in the U.S. ...